Nilotinib Stada 150 Mg Cápsulas

Nilotinib, the active ingredient in Nilotinib Stada 150 Mg Cápsulas, is a tyrosine kinase inhibitor presented as a 150 mg capsule for oral use. It treats chronic myeloid leukemia in patients who are Philadelphia chromosome‑positive. GNH USA supplies Nilotinib Stada 150 Mg Cápsulas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL pathway in chronic myeloid leukemia. - Chronic phase CML: reduces leukemic cell proliferation and helps achieve cytogenetic and molecular responses. - Accelerated phase CML: provides disease control when resistance to first‑line therapy occurs. - Blast phase CML: offers a therapeutic option for patients with advanced disease who have the Philadelphia chromosome.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in treatment. - Rash: skin erythema or pruritus. - Headache: transient and usually low‑grade. - Fatigue: general tiredness without specific cause. - Myalgia: muscle aches or stiffness.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Severe hepatic injury: jaundice, elevated transaminases. - Grade 3‑4 neutropenia: increased infection risk. - Thrombocytopenia: bleeding tendency. - Cardiovascular events: myocardial ischemia or stroke.

Patients should be monitored for cardiac, hepatic and hematologic safety. - Cardiac monitoring: obtain baseline ECG and periodically assess QT interval. - Hepatic function: check liver enzymes before initiation and during therapy. - Hematologic surveillance: perform regular complete blood counts. - Avoid strong CYP3A4 inhibitors: dose may increase and raise toxicity risk. - Adjust in hepatic impairment: consider dose reduction if moderate liver dysfunction is present. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nilotinib has several clinically relevant drug interactions that require attention. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib plasma concentrations. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, St. John’s wort): may lower nilotinib exposure and reduce efficacy. - Proton pump inhibitors: modestly affect gastric pH and could alter absorption. - Warfarin: may enhance anticoagulant effect; monitor INR closely.